• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Conversion Labs Appoints Digital Marketing Executive, Bryant Hussey, as Chief Digital Officer

    1/5/21 10:15:00 AM ET
    $CVLB
    Get the next $CVLB alert in real time by email

    NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB), a direct-to-consumer telemedicine company, has appointed digital marketing expert and industry thought-leader, Bryant Hussey, to the new position of chief digital officer. He will lead the company’s marketing and customer retention efforts, as well as help launch new or enhanced telemedicine products, improve unit economics, and maximize patient lifetime value.

    Hussey brings to Conversion Labs more than 20 years of executive experience at direct-to-consumer and eCommerce companies, translating business goals into successful marketing campaigns. He specializes in lead generation, funnel optimization and customer retention that maximizes customer lifetime value and lowers cost per acquisition.

    Hussey previously served as chief digital officer at Advanced Vita Supplements (AVS), a direct response nutraceutical company and an official global licensee of Playboy Enterprise’s sexual wellness supplements. At AVS, he was responsible for creating targeted campaigns that increased brand awareness and customer conversions, and he led the launch of the company’s subscription-based business.

    Prior to AVS, Hussey was vice president of Atlantic Coast Brands, an ‘Inc. 500’ omni-channel international beauty company that has serviced more than 10 million customers worldwide and generated $1 billion in revenue overall. He led the company’s digital marketing campaigns for its hair regrowth system for women which attracted more than 1 million customers and generated $500 million in revenue. He also grew Atlantic’s subscription-based business, adding 60,000 subscriptions per month on average over nine years.

    “Online advertising that drives subscriptions is key to our growth strategy and building shareholder value, making Bryant’s proven success in this arena a perfect fit for Conversion Labs,” stated Conversion Labs CEO, Justin Schreiber. “Bryant has shown to be especially adept at evaluating the trends in the global consumer markets, and creating online marketing campaigns that effectively address them.

    “We expect his knowledge and experience to help us fully optimize our digital marketing strategies and extract maximum value from our growing line of telemedicine products that address large and underserved markets. This includes the near-term launch of a new brand extension for our popular Rex MD line for men’s health that addresses additional medical indications.”

    Conversion Labs recently reported that its annual recurring revenue (ARR) from subscriptions reached $23.0 million, up 517% over last year, largely due to consumer demand for Rex MD.

    Earlier in his career, Hussey served as a marketing director for a division of Ardis Health, an international eCommerce company, where he focused on the digital marketing of direct-to-consumer diet products. He oversaw the company’s media distribution channels and customer acquisition in the U.S. and assisted in product and business development.

    “I couldn’t be more excited to join Conversion Labs with so many opportunities for growth in direct-to-consumer telemedicine,” said Hussey. “Creating and executing digital marketing strategies for products that make a real difference in people’s lives has long been my passion. I believe what I can bring to Conversion Labs will really make a difference, especially when teaming with the tremendous talent Justin has brought together over the last several months.”

    Hussey received his B.A. in Economics at Saint Peter’s University, and completed professional studies programs in Integrated Marketing at New York University. He is a certified Google Advertising Professional, and regularly speaks at lead generation and performance marketing events, including LeadsCon and Affiliate Summit.

    For nine years Hussey has served on the board of trustees for the House of Faith, a non-profit organization dedicated to transitional housing programs for the homeless.

    About Conversion Labs
    Conversion Labs, Inc. is a telemedicine company with a portfolio of online direct-to-consumer brands. The company’s brands combine virtual medical treatment with prescription medications and unique over-the-counter products. Its network of licensed physicians offers telemedicine services and direct-to-consumer pharmacy to consumers across the U.S. To learn more, visit Conversionlabs.com.

    Important Cautions Regarding Forward-Looking Statements
    This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things our plans, strategies and prospects -- both business and financial. Although we believe that our plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, we cannot assure you that we will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Many of the forward-looking statements contained in this news release may be identified by the use of forward-looking words such as "believe," "expect," "anticipate," "should," "planned," "will," "may," "intend," "estimated," and "potential," among others. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include market conditions and those set forth in reports or documents that we file from time to time with the United States Securities and Exchange Commission. All forward-looking statements attributable to Conversion Labs, Inc. or a person acting on its behalf are expressly qualified in their entirety by this cautionary language.

    Company Contact                                
    Conversion Labs                                
    Juan Manuel Piñeiro Dagnery                        
    CFO                                                
    Email Contact        

    Media and Investor Relations Contact
    Ron Both or Grant Stude
    CMA Investor Relations
    Tel (949) 432-7566
    Email Contact


    Get the next $CVLB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CVLB

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CVLB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Conversion Labs, Inc.

      SC 13D - LifeMD, Inc. (0000948320) (Subject)

      3/19/21 4:15:12 PM ET
      $CVLB

    $CVLB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research reiterated coverage on Conversion Labs with a new price target

      BTIG Research reiterated coverage of Conversion Labs with a rating of Buy and set a new price target of $40.00 from $15.00 previously

      2/18/21 9:19:07 AM ET
      $CVLB
    • B. Riley FBR initiated coverage on Conversion Labs with a new price target

      B. Riley FBR initiated coverage of Conversion Labs with a rating of Buy and set a new price target of $35.00

      2/5/21 6:59:45 AM ET
      $CVLB

    $CVLB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Conversion Labs Begins Trading Under New Company Name, LifeMD, and Ticker Symbol, LFMD

      NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB) (NASDAQ: LFMD), a leading direct-to-patient telehealth company, will begin trading at the opening of the market today under its new name, LifeMD, Inc., and Nasdaq ticker symbol, LFMD. The stock’s new CUSIP number will be 53216B 104. “Our new name reflects our evolution from a healthcare-focused performance marketing business into a leading provider of personalized, direct to patient telehealth services,” stated Justin Schreiber, LifeMD’s co-founder and CEO. “Our vision is to radically change healthcare by making access to the best physicians and prescription medications easily accessible, convenient, and aff

      2/22/21 3:30:00 AM ET
      $CVLB
    • Conversion Labs to Become Life MD™ with Launch of New Concierge Telehealth Services

      NEW YORK, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB), a leading direct-to-patient telehealth company, will change its name to Life MD™ on February 22, followed by the official launch of its subscription-based primary care and concierge services offering designed to positively transform all aspects of a patient’s healthcare. “We see our new name reflecting our evolution and expansion from a branded telemedicine products company into a leading provider of end-to-end concierge telehealth services,” stated company co-founder and CEO, Justin Schreiber. “Life MD expresses our desire to have a deeper connection to the daily lives of our patients who desire more conven

      2/12/21 8:30:00 AM ET
      $CVLB
    • Conversion Labs Appoints Seasoned Financial and Operational Executive, Marc Benathen, as Chief Financial Officer

      NEW YORK, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB), a leading direct-to-consumer telemedicine company, has appointed Marc Benathen as chief financial officer, effective March 1. He succeeds Juan Manuel Piñeiro Dagnery, who will continue as chief revenue officer. Benathen is an accomplished senior financial and operational executive with 18 years of experience leading multiple areas of finance and operations, including corporate strategy, procurement and supply chain, technology, legal and customer service. He also brings to the company experience in team building and leading complex capital market transactions, M&A and joint ventures, as well as leadership of

      2/5/21 8:31:00 AM ET
      $CVLB

    $CVLB
    Leadership Updates

    Live Leadership Updates

    See more
    • Conversion Labs Appoints Seasoned Financial and Operational Executive, Marc Benathen, as Chief Financial Officer

      NEW YORK, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB), a leading direct-to-consumer telemedicine company, has appointed Marc Benathen as chief financial officer, effective March 1. He succeeds Juan Manuel Piñeiro Dagnery, who will continue as chief revenue officer. Benathen is an accomplished senior financial and operational executive with 18 years of experience leading multiple areas of finance and operations, including corporate strategy, procurement and supply chain, technology, legal and customer service. He also brings to the company experience in team building and leading complex capital market transactions, M&A and joint ventures, as well as leadership of

      2/5/21 8:31:00 AM ET
      $CVLB
    • Conversion Labs Appoints Leading Telehealth Professional, Dr. Anthony Puopolo, as Chief Medical Officer

      NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB), a direct-to-consumer telemedicine company, has appointed licensed personal care and wellness physician and psychiatrist, Dr. Anthony Puopolo, to the new position of chief medical officer. Dr. Puopolo will be responsible for overseeing the company’s rapidly expanding network of state licensed physicians and ensuring that the company is delivering the highest quality of care. He will also work closely with Conversion Labs’ product and marketing teams to optimize the company’s telemedicine offerings and support expansion into new verticals. Dr. Puopolo brings to Conversion Labs more than 20 years of execut

      1/11/21 8:31:00 AM ET
      $CVLB
    • Conversion Labs Appoints Digital Marketing Executive, Bryant Hussey, as Chief Digital Officer

      NEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (NASDAQ: CVLB), a direct-to-consumer telemedicine company, has appointed digital marketing expert and industry thought-leader, Bryant Hussey, to the new position of chief digital officer. He will lead the company’s marketing and customer retention efforts, as well as help launch new or enhanced telemedicine products, improve unit economics, and maximize patient lifetime value. Hussey brings to Conversion Labs more than 20 years of executive experience at direct-to-consumer and eCommerce companies, translating business goals into successful marketing campaigns. He specializes in lead generation, funnel optimization and custo

      1/5/21 10:15:00 AM ET
      $CVLB

    $CVLB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: David Happy Walters was granted 1,200,000 units of Common Stock, increasing ownership by 149% to 1,336,300 units

      4 - LifeMD, Inc. (0000948320) (Issuer)

      2/26/21 10:04:47 AM ET
      $CVLB
    • SEC Form 4: Harold Eric Yecies bought $100,400 worth of Common Stock (5,000 units at $20.08)

      4 - LifeMD, Inc. (0000948320) (Issuer)

      2/25/21 7:16:47 PM ET
      $CVLB
    • SEC Form 4: Michael Brad Roberts bought $102,500 worth of Common Stock (5,000 units at $20.50)

      4 - LifeMD, Inc. (0000948320) (Issuer)

      2/25/21 6:13:10 PM ET
      $CVLB

    $CVLB
    SEC Filings

    See more
    • SEC Form 8-K filed

      8-K - LifeMD, Inc. (0000948320) (Filer)

      2/26/21 5:00:48 PM ET
      $CVLB
    • SEC Form 8-K filed

      8-K - CONVERSION LABS, INC. (0000948320) (Filer)

      2/22/21 7:30:16 AM ET
      $CVLB
    • SEC Form 8-K filed

      8-K - CONVERSION LABS, INC. (0000948320) (Filer)

      2/12/21 8:30:10 AM ET
      $CVLB